

# Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation

NCT07368634

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Daihong Liu
Enrollment	18 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Age ≥ 18 years at the time of enrollment.
- History of allogeneic hematopoietic stem cell transplantation.
- Presence of Epstein-Barr virus (EBV) DNAemia confirmed by quantitative polymerase chain reaction (qPCR) in peripheral blood.
- EBV DNAemia persisting or increasing despite standard management, as determined by the investigator.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

... and 2 more (see full listing online)

### Exclusion (8)

- Diagnosis of EBV-associated lymphoproliferative disorder requiring immediate cytotoxic chemotherapy.
- Active, uncontrolled infection other than EBV.
- History of severe autoimmune disease requiring systemic immunosuppressive therapy.
- Uncontrolled graft-versus-host disease requiring high-dose systemic corticosteroids or other immunosuppressive treatment.
- Prior treatment with EBV-specific adoptive T cell therapy within a defined washout period.

... and 3 more (see full listing online)

## Locations (1 total)

---

Chinese PLA General Hospital, Beijing, China